Nordic Life Science Days Digital, 20-23 April 2021.

NLS Days is the largest Nordic partnering conference dedicated to the life science industry. NLS Days offers networking and knowledge for anyone interested in the Nordic life science, biotech, pharma, medical devices and e-health business. It’s a space for meaningful encounters, with one-on-one meetings being one of the main features. Additionally, the high quality of topics and presenters provide insight into the most recent trends in science and business.

(May 2020)

BIO Digital, 10-11 & 14-18 June 2021

Xplico is joining the world's largest global biotech partnering experience on June 10-11 & 14-18.

BIO Digital is the world's largest virtual biotech partnering and education event, convening thousands of global biotech leaders and innovators. Join us in our efforts to accelerate a BIO-Revolution through global partnerships, collaboration, and thought leadership.

Now more than ever, the world is counting on us to come together to advance innovation and discovery. 

(April 2021)

XVI International Pharma Licensing Symposium, Brighton UK, 15-17 September 2021

Following the postponement of last year’s event the Pharmaceutical Licensing Group UK is hosting the XVI International Pharma Licensing Symposium (IPLS) and bringing the event to Brighton from September 15^th to 17^th 2021. IPLS is a well-established international life science networking conference now in its 16th year. IPLS is a great opportunity for the healthcare deal-making community to come together to learn, discuss, network and partner.

(April 2021)

BioPharm America, 20-23 September 2021.

BioPharm America attracts a wide range of business leaders, including senior executives of leading biotech companies, business development teams from large and midsize pharmaceutical companies, investors and other industry experts and it’s the perfect opportunity to engage with global life science partners. BioPharm America is where biotech industry partnerships get started.

(April 2021)

Xplico elected a Gazelle Company for the 4th year in a row

We are proud to announce that Xplico has been elected a Gazelle company for the 4^th year in a row.

The election is organized by the Danish financial newspaper Børsen, and the requirements to become a Gazelle company are tough. A Gazelle business is continuously growing and, as a minimum, doubles its revenue or gross profit over four fiscal years, while maintaining positive growth throughout the years.

It is quite impressive that we have been able to live up to this four years in a row and we express our gratitude to our customers because without their continuous support and trust this would not have been possible.

(October 2019)

The new Xplico Evaluator template is now released

Xplico proudly releases a new and enhanced version of Xplico Evaluator, our valuation tool, available for all our subscription customers.

Many things have been changed behind the scene, with only a few changes in the way the assumptions are entered. The new version can handle more advanced Deal Terms and it has more features as well as additional outputs.

(June 2019)

Publication of the Xplico Valuation Survey

(November 2018)

Xplico article for Biotech & Money / LSX

In an article for Biotech & Money / LSX – The Network For Life Science Executives, our partner, Finn Nikolajsen, gives his point of view on the challenges of the ownership structures that the biotech companies and their investors face when they try to analyze the consequences of current and future funding rounds and exits.

Read the full article

(October 2018)

Xplico article for Biotech & Money / LSX

In an article for Biotech & Money / LSX – The Network For Life Science Executives, our partner, Uffe Boesen, gives his point of view on the challenges that the Nordic life science companies face.

Read the full article

(August 2018)

Xplico Interview with Biotech & Money / LSX

In an interview with Biotech & Money / LSX – The Network For Life Science Executives, our partner, Uffe Boesen, explains how valuation is critical for strategic decision-making and points out to some of the common pitfalls companies encounter when using valuation models that are built in house.

Read the interview

(June 2018)